(PDF) P043 Cost-Effectiveness Analysis of Different

P043 Cost-Effectiveness Analysis of Different Sequences of Osimertinib Administration for EGFR-Mutated Non-Small-Cell Lung Cancer

Journal of Thoracic Oncology - United States

doi 10.1016/j.jtho.2018.10.066

Full Text

Abstract

Available in full text

Categories

Respiratory Medicine

Date

December 1, 2018

Authors

Publisher

Elsevier BV

Related search

Ce4 - Cost-Effectiveness Analysis of First-Line Osimertinib in Patients With Egfr Mutation-Positive Non-Small Cell Lung Cancer

Value in Health

Occupational Health

English

Cost‐Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR‐Mutation‐Positive Non‐Small Cell Lung Cancer

Cancer Research

English

P2.13-13 Real-World Study of Osimertinib in EGFR T790m-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis

Journal of Thoracic Oncology

Respiratory Medicine

English

Osimertinib (AZD9291) Increases Radio‑sensitivity in EGFR T790M Non‑small Cell Lung Cancer

Oncology Reports

Cancer Research

English

P2.01-29 Economic Analysis of Osimertinib in Previously Untreated EGFR-Positive Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

Pcn169 - A Flexible Open-Source Cost-Effectiveness Model for Metastatic Egfr+ Non-Small Cell Lung Cancer

Value in Health

Occupational Health

English

Overall Survival Analysis and Characterization of an EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) Population

Archivos de Bronconeumologia

Respiratory Medicine

English

Patient-Reported Outcomes From FLAURA: Osimertinib Versus Erlotinib or Gefitinib in Patients With EGFR-mutated Advanced Non-Small-Cell Lung Cancer

European Journal of Cancer

Cancer Research

English

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients With EGFR-T790M Mutation

Cancer Research

English